Acetazolamide Improves Right Ventricular Function and Metabolic Gene Dysregulation in Experimental Pulmonary Arterial Hypertension
暂无分享,去创建一个
B. Kalish | S. Kourembanas | Sally H Vitali | H. Christou | Z. Michael | Benjamin Finander | F. Spyropoulos | Kosmas Kosmas | Panagiotis Zymaris | Brian T. Kalish
[1] J. Rabinowitz,et al. Comprehensive quantification of fuel use by the failing and nonfailing human heart , 2020, Science.
[2] F. Spyropoulos,et al. Echocardiographic markers of pulmonary hemodynamics and right ventricular hypertrophy in rat models of pulmonary hypertension The first two authors contributed equally to this manuscript. , 2020, Pulmonary circulation.
[3] H. Hudalla,et al. Carbonic Anhydrase Inhibition Ameliorates Inflammation and Experimental Pulmonary Hypertension. , 2019, American journal of respiratory cell and molecular biology.
[4] J. Nielsen-Kudsk,et al. Right Ventricular Fibrosis: A Pathophysiological Factor in Pulmonary Hypertension? , 2019, Circulation.
[5] T. Michel,et al. Chemogenetic generation of hydrogen peroxide in the heart induces severe cardiac dysfunction , 2018, Nature Communications.
[6] David E. Irwin,et al. Vascular Adaptation of the Right Ventricle in Experimental Pulmonary Hypertension , 2018, American journal of respiratory cell and molecular biology.
[7] Charles T. Hindmarch,et al. Transcriptomic Signature of Right Ventricular Failure in Experimental Pulmonary Arterial Hypertension: Deep Sequencing Demonstrates Mitochondrial, Fibrotic, Inflammatory and Angiogenic Abnormalities , 2018, International journal of molecular sciences.
[8] I. Douglas,et al. Assessment of Right Ventricular Function in the Research Setting: Knowledge Gaps and Pathways Forward. An Official American Thoracic Society Research Statement , 2018, American journal of respiratory and critical care medicine.
[9] G. Hansmann,et al. PPARγ agonist pioglitazone reverses pulmonary hypertension and prevents right heart failure via fatty acid oxidation , 2018, Science Translational Medicine.
[10] M. Goumans,et al. Contribution of Impaired Parasympathetic Activity to Right Ventricular Dysfunction and Pulmonary Vascular Remodeling in Pulmonary Arterial Hypertension , 2017, Circulation.
[11] K. Wagner,et al. Echocardiographic and Histological Examination of Cardiac Morphology in the Mouse. , 2017, Journal of visualized experiments : JoVE.
[12] A. van Rossum,et al. Renal Denervation Reduces Pulmonary Vascular Remodeling and Right Ventricular Diastolic Stiffness in Experimental Pulmonary Hypertension , 2017, JACC. Basic to translational science.
[13] E. Michelakis,et al. A Paradigm Shift Is Needed in the Field of Pulmonary Arterial Hypertension for Its Entrance Into the Precision Medicine Era. , 2016, Circulation research.
[14] B. Alvarez,et al. Carbonic anhydrase inhibitors reduce cardiac dysfunction after sustained coronary artery ligation in rats. , 2016, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.
[15] B. Maron,et al. Molecular Mechanisms of Pulmonary Vascular Remodeling in Pulmonary Arterial Hypertension , 2016, International journal of molecular sciences.
[16] N. Serkova,et al. Severe pulmonary hypertension is associated with altered right ventricle metabolic substrate uptake. , 2015, American journal of physiology. Lung cellular and molecular physiology.
[17] E. Michelakis,et al. Emerging therapies and future directions in pulmonary arterial hypertension. , 2015, The Canadian journal of cardiology.
[18] L. Farkas,et al. Iloprost reverses established fibrosis in experimental right ventricular failure , 2015, European Respiratory Journal.
[19] E. Michelakis,et al. The Metabolic Theory of Pulmonary Arterial Hypertension , 2014, Circulation research.
[20] W. Fang,et al. The Ratio of 18F-FDG Activity Uptake Between the Right and Left Ventricle in Patients With Pulmonary Hypertension Correlates With the Right Ventricular Function , 2014, Clinical nuclear medicine.
[21] E. Michelakis,et al. The metabolic basis of pulmonary arterial hypertension. , 2014, Cell metabolism.
[22] L. Gleaves,et al. Evidence for right ventricular lipotoxicity in heritable pulmonary arterial hypertension. , 2014, American journal of respiratory and critical care medicine.
[23] E. Ruoslahti,et al. A novel vascular homing peptide strategy to selectively enhance pulmonary drug efficacy in pulmonary arterial hypertension. , 2014, The American journal of pathology.
[24] Robert L. Arechederra,et al. Effect of sulfonamides as carbonic anhydrase VA and VB inhibitors on mitochondrial metabolic energy conversion. , 2013, Bioorganic & medicinal chemistry.
[25] James D. Thomas,et al. Fasting 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography to detect metabolic changes in pulmonary arterial hypertension hearts over 1 year. , 2013, Annals of the American Thoracic Society.
[26] J. Bigbee,et al. Metabolic Gene Remodeling and Mitochondrial Dysfunction in Failing Right Ventricular Hypertrophy Secondary to Pulmonary Arterial Hypertension , 2013, Circulation. Heart failure.
[27] J. Loscalzo,et al. Pulmonary hypertension: pathophysiology and signaling pathways. , 2013, Handbook of experimental pharmacology.
[28] S. Kourembanas,et al. Improved pulmonary vascular reactivity and decreased hypertrophic remodeling during nonhypercapnic acidosis in experimental pulmonary hypertension. , 2012, American journal of physiology. Lung cellular and molecular physiology.
[29] J. Richalet,et al. Acetazolamide and chronic hypoxia: effects on haemorheology and pulmonary haemodynamics , 2012, European Respiratory Journal.
[30] W. Paulus,et al. Bisoprolol Delays Progression Towards Right Heart Failure in Experimental Pulmonary Hypertension , 2012, Circulation. Heart failure.
[31] N. Ozdemir,et al. Increased Right Ventricular Glucose Metabolism in Patients With Pulmonary Arterial Hypertension , 2011, Clinical nuclear medicine.
[32] J. Klinger,et al. Bosentan attenuates right ventricular hypertrophy and fibrosis in normobaric hypoxia model of pulmonary hypertension. , 2011, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[33] P. Fawcett,et al. Molecular signature of a right heart failure program in chronic severe pulmonary hypertension. , 2011, American journal of respiratory cell and molecular biology.
[34] V. Beneš,et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. , 2009, Clinical chemistry.
[35] L. Fredenburgh,et al. Cyclooxygenase-2 inhibition and hypoxia-induced pulmonary hypertension: effects on pulmonary vascular remodeling and contractility. , 2009, Trends in cardiovascular medicine.
[36] I. Haber,et al. The inhibition of pyruvate dehydrogenase kinase improves impaired cardiac function and electrical remodeling in two models of right ventricular hypertrophy: resuscitating the hibernating right ventricle , 2009, Journal of Molecular Medicine.
[37] Thomas D. Schmittgen,et al. Analyzing real-time PCR data by the comparative CT method , 2008, Nature Protocols.
[38] Claudiu T. Supuran,et al. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators , 2008, Nature Reviews Drug Discovery.
[39] J. Bronzwaer,et al. Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertension. , 2007, European heart journal.
[40] E. Swenson,et al. Inhibition of hypoxia-induced calcium responses in pulmonary arterial smooth muscle by acetazolamide is independent of carbonic anhydrase inhibition. , 2007, American journal of physiology. Lung cellular and molecular physiology.
[41] P. Light,et al. Carbonic anhydrase inhibition prevents and reverts cardiomyocyte hypertrophy , 2007, The Journal of physiology.
[42] Y. Kagaya,et al. Increased [18F]fluorodeoxyglucose accumulation in right ventricular free wall in patients with pulmonary hypertension and the effect of epoprostenol. , 2005, Journal of the American College of Cardiology.
[43] K. Sluka,et al. Acetazolamide, a Carbonic Anhydrase Inhibitor, Reverses Inflammation-Induced Thermal Hyperalgesia in Rats , 2005, Journal of Pharmacology and Experimental Therapeutics.
[44] C. Hsieh,et al. Prevention of Hypoxia-Induced Pulmonary Hypertension by Enhancement of Endogenous Heme Oxygenase-1 in the Rat. • 238 , 1997, Pediatric Research.